Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results.
Roberto Pili
No relevant relationships to disclose
Li Shen
No relevant relationships to disclose
Saby George
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Anita Sandecki
No relevant relationships to disclose
Connie Collins
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose